Rivaroxaban is Comparable to Warfarin in Prevention of Thromboembolism in Patients with Non-Valvular Atrial Fibrillation with Valvular Heart Disease: A Systematic Review and Meta-analysis
Baral, N.; Katel, A.; Adhikari, G.; Khan, M. R.; Khan, H. M. W.; Rauniyar, R.; Akanbi, M.; Malik, B.; Ahmad, M.; Khan, A.; Abdelazeem, B.; Savarapu, P.; Isa, S. O.; Kunadi, A.; Sud, P.; Changezi, H. U.
Show abstract
ObjectivesWhile the use of novel oral anticoagulants (NOACs) has been approved in the treatment of non-valvular atrial fibrillation (NVAF), we are lacking studies on individual NOACs in NVAF with valvular heart disease (VHD) including bio-prosthetic valve and valve repair. We aimed to determine the efficacy and safety of rivaroxaban compared to warfarin in prevention of thromboembolism in patients with NVAF with VHD. MethodsWe searched PubMed, MEDLINE, and EMBASE including only RCTs and Cohort studies from inception till April 2021. Eligible studies compared rivaroxaban with warfarin in patients with NVAF with VHD. We excluded patients with valvular AF. We used Review Manager (version 5.4, Cochrane Collaboration, Oxford, UK) applying the Mantel-Haenszel test and followed PRISMA guidelines. Risk ratio (RR) and 95% confidence intervals (CIs) were estimated using a random-effects method and heterogeneity using I squared test. ResultsWe had total of 23136 participants in both groups. Our results showed stroke and systemic thromboembolism in 88 of 4258 (2.06%) patients in the rivaroxaban group compared to 351 of 18878 (1.85%) patients in the warfarin group (RR 0.76; 95% CI, 0.55, 1.06; heterogeneity I2 = 35%, P = 0.10), major bleeding in 247 of 4258 (5.8%) patients in the rivaroxaban group compared to 270 of 18879 (1.4%) patients in the warfarin group (HR 1.68; 95% CI, 0.59, 4.77; heterogeneity I2 = 97%) and intracranial hemorrhage in 24 out of 2583 (0.9%) patients in the rivaroxaban group compared to 35 of 2160 (1.6%) in warfarin group (HR 0.49; 95% CI, 0.16, 1.56; heterogeneity I2 = 70%). ConclusionsOur results show that rivaroxaban is comparable to warfarin in prevention of stroke and systemic thromboembolism in patients with NVAF with VHD. Rivaroxaban is also comparable to warfarin in bleeding risks in these patients. REGISTRATION NUMBERCRD42021222490
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Cost-effectiveness analysis of patent foramen ovale closure versus medical therapy alone after cryptogenic stroke 95%
- Intravenous Thrombolysis for Acute Central Retinal Artery Occlusion: Protocol For a Systematic Review and Individual Participant Data Meta-Analysis of Randomized Controlled Trials 94%
- The usefulness of D-dimer as a predictive marker for mortality in patients with COVID-19 hospitalized during the first wave in Italy 93%
Similar papers in this journal
- Anticoagulation trends in adults aged 65 and over with atrial fibrillation; a cohort study 93%
- Vascular Comorbidities Worsen Prognosis of Patients with Heart Failure Hospitalized with COVID-19 92%
- Comparison of troponin and natriuretic peptides in takotsubo syndrome and acute coronary syndrome: a meta-analysis 92%
Similar papers in this journal
- Ticagrelor vs Clopidogrel: the Impact of Platelet Inhibition on Cerebrovascular Microembolic Events during TAVR 95%
- Direct Oral Anticoagulants Affect Activated Clotting Time During and Bleeding Events After Percutaneous Coronary Intervention 94%
- Cardiac and Perinatal Outcomes Among Pregnancies with Maternal Cardiac Arrhythmias 92%
Similar papers in this journal
- Outcome Disparities by Insurance Plan and Educational Attainment in Patients with Atrial Fibrillation 95%
- Original Research; Quality Assessment And Comparative Analysis On The Recommendations Of Current Guidelines On Screening And Diagnosis Of Peripheral Arterial Disease; A Systematic Review 92%
- Reporting of Retrospective Registration in Clinical Trial Publications 92%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.